DaVita Inc. (DVA) Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. DaVita Inc. is a leading provider of kidney dialysis services in the United States, operating through its U.S. dialysis business, U.S. integrated kidney care (IKC), other ancillary services, and international operations. The company reported as a large accelerated filer with approximately 83.9 million shares of common stock outstanding as of August 2, 2024.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2024) | Value (in millions) |
|---|---|
| Total Revenues | $6,257.3 |
| Operating Income | $990.2 |
| Net Income Attributable to DaVita Inc. | $462.3 |
| Diluted EPS | $5.15 |
| Net Cash Provided by Operating Activities | $664.0 |
| Free Cash Flow | $327.0 |
| Total Debt (Principal Outstanding) | $9,048.2 |
| Cash and Cash Equivalents | $416.5 |
| Available Revolving Credit | $1,240.0 |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 6.5% year-over-year (YTD) to $6.257 billion, driven by a 4.8% increase in U.S. dialysis revenues and a 22.4% increase in ancillary services revenues.
- Profitability: Operating income rose 38.1% YTD to $990.2 million. Net income attributable to DaVita Inc. increased 57.1% YTD to $462.3 million.
- Volume: U.S. dialysis treatments increased 0.5% YTD, with average treatments per day rising slightly. Normalized non-acquired treatment growth was 0.4% in Q2.
- One-Time Items: The six-month period included a non-cash gain of $35.1 million from the consolidation of a previously nonconsolidated dialysis partnership. Conversely, the company incurred $29.9 million in U.S. dialysis center closure costs.
- Change Healthcare (CHC) Impact: The CHC cybersecurity outage caused significant delays in claims processing and collections, increasing Days Sales Outstanding (DSO) to 59 days from 54 days at year-end 2023. This negatively impacted operating cash flow, which decreased 27.3% YTD.
Guidance, Outlook, and Risks
- Outlook: Management expects DSOs to continue declining as claims submissions normalize, though payment collection delays persist. The company anticipates continued pressure from elevated labor costs, inflation, and supply chain challenges.
- Capital Allocation: The company repurchased 4.77 million shares for $615.9 million during the first six months of 2024. Approximately $543 million remains available under the current repurchase authorization.
- Debt Management: In May 2024, the company amended its credit agreement to extend the maturity of a portion of its Term Loan B-1 to May 2031. The weighted average effective interest rate on all debt was 4.39% for the six months ended June 30, 2024.
- Risks: Key risks include the ongoing resolution of the CHC outage, potential regulatory changes regarding non-compete agreements (FTC rule), elevated mortality rates affecting patient census, and the complexity of revenue recognition for value-based care contracts.
Investor Verification Checklist
- CHC Recovery Status: Verify the trajectory of Days Sales Outstanding (DSO) reduction and the extent of any permanent revenue loss or bad debt write-offs resulting from the Change Healthcare outage.
- Center Closure Costs: Monitor the run-rate of center closure charges ($29.9 million YTD) and their impact on future operating margins as the company optimizes its footprint.
- Non-GAAP Adjustments: Review the reconciliation of Adjusted Operating Income, noting the recent change in presentation to include center closure costs, which affects period-over-period comparability.
- Debt Covenants: Confirm compliance with the maximum leverage ratio covenant (5.00:1.00 through June 2026) given the recent debt restructuring and cash flow volatility.
- Regulatory Exposure: Assess the potential financial impact of the FTC's proposed ban on non-compete clauses and ongoing investigations (e.g., U.S. Attorney Colorado, California Department of Insurance).